

Ramon Lecumberri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6630828/publications.pdf>

Version: 2024-02-01

112
papers

4,032
citations

147726

31
h-index

123376

61
g-index

127
all docs

127
docs citations

127
times ranked

4466
citing authors

#	ARTICLE	IF	CITATIONS
1	International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 56-70.	1.9	469
2	2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. <i>Lancet Oncology</i> , The, 2019, 20, e566-e581.	5.1	458
3	International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 71-80.	1.9	252
4	2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. <i>Lancet Oncology</i> , The, 2022, 23, e334-e347.	5.1	138
5	Direct oral anticoagulants in the treatment of acute venous thromboembolism: A systematic review and meta-analysis. <i>Thrombosis Research</i> , 2014, 134, 774-782.	0.8	113
6	Venous thromboembolism during pregnancy or postpartum: Findings from the RIETE Registry. <i>Thrombosis and Haemostasis</i> , 2007, 97, 186-190.	1.8	111
7	Antithrombin Cambridge II (A384S): an underestimated genetic risk factor for venous thrombosis. <i>Blood</i> , 2007, 109, 4258-4263.	0.6	104
8	Screening for Occult Cancer in Patients With Unprovoked Venous Thromboembolism. <i>Annals of Internal Medicine</i> , 2017, 167, 410.	2.0	96
9	Discovery of Anticoagulant Drugs: A Historical Perspective. <i>Current Drug Discovery Technologies</i> , 2012, 9, 83-104.	0.6	96
10	Dynamics of case-fatality rates of recurrent thromboembolism and major bleeding in patients treated for venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2013, 110, 834-843.	1.8	94
11	Maintained effectiveness of an electronic alert system to prevent venous thromboembolism among hospitalized patients. <i>Thrombosis and Haemostasis</i> , 2008, 100, 699-704.	1.8	92
12	The Clinical Course of Venous Thromboembolism May Differ According to Cancer Site. <i>American Journal of Medicine</i> , 2017, 130, 337-347.	0.6	83
13	Thrombophilia testing in patients with venous thromboembolism. Findings from the RIETE registry. <i>Thrombosis Research</i> , 2009, 124, 174-177.	0.8	78
14	Multiple Myeloma Patients Have a Specific Serum Metabolomic Profile That Changes after Achieving Complete Remission. <i>Clinical Cancer Research</i> , 2013, 19, 4770-4779.	3.2	77
15	Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 1010-1018.	1.9	77
16	Consenso nacional sobre el diagnóstico, estratificación de riesgo y tratamiento de los pacientes con tromboembolia pulmonar. <i>Archivos De Bronconeumología</i> , 2013, 49, 534-547.	0.4	70
17	Direct-acting oral anticoagulants: pharmacology, indications, management, and future perspectives. <i>European Journal of Haematology</i> , 2015, 95, 389-404.	1.1	70
18	Meta-Analysis of Reversal Agents for Severe Bleeding Associated With Direct Oral Anticoagulants. <i>Journal of the American College of Cardiology</i> , 2021, 77, 2987-3001.	1.2	69

#	ARTICLE	IF	CITATIONS
19	D-dimer levels correlate with mortality in patients with acute pulmonary embolism: Findings from the RIETE registry. <i>Critical Care Medicine</i> , 2007, 35, 1937-1941.	0.4	67
20	The Khorana score for prediction of venous thromboembolism in cancer patients: An individual patient data meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1940-1951.	1.9	60
21	A nonsense polymorphism in the protein Z-dependent protease inhibitor increases the risk for venous thrombosis. <i>Blood</i> , 2006, 108, 177-183.	0.6	58
22	Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: Results from the ABEL study. <i>Thrombosis Research</i> , 2013, 132, 666-670.	0.8	57
23	Elevated white blood cell count and outcome in cancer patients with venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2008, 100, 905-911.	1.8	56
24	Occult cancer screening in patients with venous thromboembolism: guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 2076-2079.	1.9	56
25	Case Fatality Rates of Recurrent Thromboembolism and Bleeding in Patients Receiving Direct Oral Anticoagulants for the Initial and Extended Treatment of Venous Thromboembolism. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2015, 20, 490-500.	1.0	53
26	Development of a Risk Prediction Score for Occult Cancer in Patients With VTE. <i>Chest</i> , 2017, 151, 564-571.	0.4	51
27	Specific Antidotes in Development for Reversal of Novel Anticoagulants: A Review. <i>Recent Patents on Cardiovascular Drug Discovery</i> , 2015, 9, 2-10.	1.5	50
28	New parenteral anticoagulants in development. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2011, 5, 33-59.	1.0	46
29	Therapeutic versus Prophylactic Bemiparin in Hospitalized Patients with Nonsevere COVID-19 Pneumonia (BEMICOP Study): An Open-Label, Multicenter, Randomized, Controlled Trial. <i>Thrombosis and Haemostasis</i> , 2022, 122, 295-299.	1.8	40
30	Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis. <i>Blood Cancer Journal</i> , 2021, 11, 34.	2.8	39
31	Spectrum of Atypical Clinical Presentations in Patients with Biallelic <i>PRF1</i> Missense Mutations. <i>Pediatric Blood and Cancer</i> , 2015, 62, 2094-2100.	0.8	38
32	Correlation between thrombus regression and recurrent venous thromboembolism. Examining venographic and clinical effects of low-molecular-weight heparins: a meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2004, 2, 1581-1587.	1.9	30
33	ABO blood group and risk of venous or arterial thrombosis in carriers of factor V Leiden or prothrombin G20210A polymorphisms. <i>Haematologica</i> , 2008, 93, 729-734.	1.7	29
34	POEMS syndrome with severe neurological damage clinically recovered with lenalidomide. <i>Haematologica</i> , 2012, 97, 320-322.	1.7	29
35	EHA Guidelines on Management of Antithrombotic Treatments in Thrombocytopenic Patients With Cancer. <i>HemaSphere</i> , 2022, 6, e750.	1.2	29
36	A RIETE registry analysis of recurrent thromboembolism and hemorrhage in patients with catheter-related thrombosis. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2015, 3, 243-250.e1.	0.9	28

#	ARTICLE	IF	CITATIONS
37	Treatment with daratumumab in patients with relapsed/refractory AL amyloidosis: a multicentric retrospective study and review of the literature. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2020, 27, 163-167.	1.4	27
38	New Anticoagulants: Focus on Venous Thromboembolism. <i>Current Vascular Pharmacology</i> , 2009, 7, 309-329.	0.8	26
39	Potential role of new anticoagulants for prevention and treatment of venous thromboembolism in cancer patients. <i>Vascular Health and Risk Management</i> , 2013, 9, 207.	1.0	26
40	Short Leukocyte Telomere Length Is Associated With Cardioembolic Stroke Risk in Patients With Atrial Fibrillation. <i>Stroke</i> , 2016, 47, 863-865.	1.0	26
41	Screening for occult malignancy with FDGâ€PET/CT in patients with unprovoked venous thromboembolism. <i>International Journal of Cancer</i> , 2013, 133, 2157-2164.	2.3	24
42	Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review. <i>Vascular Health and Risk Management</i> , 2014, 10, 627.	1.0	23
43	Evaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysis. <i>Lancet Haematology</i> , 2020, 7, e746-e755.	2.2	21
44	Economic impact of an electronic alert system to prevent venous thromboembolism in hospitalised patients. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 1108-1115.	1.9	20
45	Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis. <i>Leukemia</i> , 2019, 33, 1256-1267.	3.3	20
46	High incidence of venous thromboembolism despite electronic alerts for thromboprophylaxis in hospitalised cancer patients. <i>Thrombosis and Haemostasis</i> , 2013, 110, 184-190.	1.8	19
47	Anticoagulant treatment and survival in cancer patients. The evidence from clinical studies. <i>Haematologica</i> , 2005, 90, 1258-66.	1.7	19
48	Secondary myelodysplastic syndrome after treatment for promyelocytic leukemia. <i>Cancer Genetics and Cytogenetics</i> , 2003, 143, 178-181.	1.0	18
49	Implementation of a management protocol for massive bleeding reduces mortality in non-trauma patients: Results from a single centre audit. <i>Medicina Intensiva</i> , 2016, 40, 550-559.	0.4	18
50	Venous Thrombosis within 30 Days after Vaccination against SARS-CoV-2 in a Multinational Venous Thromboembolism Registry. <i>Viruses</i> , 2022, 14, 178.	1.5	18
51	Cancer-Associated Thrombosis: Beyond Clinical Practice Guidelinesâ€A Multidisciplinary (SEMIâ€SEOMâ€SETH) Expert Consensus. <i>TH Open</i> , 2018, 02, e373-e386.	0.7	17
52	Clinical characteristics of patients with factor V Leiden or prothrombin G20210A and a first episode of venous thromboembolism. Findings from the RIETE Registry. <i>Thrombosis Research</i> , 2010, 126, 283-286.	0.8	16
53	Analysis of noncatheter-associated upper extremity deep venous thrombosis from the RIETE registry. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2017, 5, 18-24.e1.	0.9	15
54	Firstâ€line use of rituximab correlates with increased overall survival in late postâ€transplant lymphoproliferative disorders: retrospective, singleâ€centre study. <i>European Journal of Haematology</i> , 2017, 98, 38-43.	1.1	14

#	ARTICLE	IF	CITATIONS
55	Screening for cancer in patients with unprovoked venous thromboembolism; protocol for a systematic review and individual patient data meta-analysis. <i>BMJ Open</i> , 2017, 7, e015562.	0.8	14
56	Effect of the time of diagnosis on outcome in patients with acute venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2011, 105, 45-51.	1.8	13
57	Management and outcomes of cancer patients with venous thromboembolism presenting with thrombocytopenia. <i>Thrombosis Research</i> , 2020, 195, 139-145.	0.8	12
58	Consenso multidisciplinar para el manejo de la tromboembolia de pulmÃ³n. <i>Archivos De Bronconeumologia</i> , 2022, 58, 246-254.	0.4	12
59	FOTROCAN Delphi consensus statement regarding the prevention and treatment of cancer-associated thrombosis in areas of uncertainty and low quality of evidence. <i>Clinical and Translational Oncology</i> , 2017, 19, 997-1009.	1.2	11
60	Insights into venous thromboembolism prevention in hospitalized cancer patients: Lessons from a prospective study. <i>PLoS ONE</i> , 2018, 13, e0200220.	1.1	11
61	Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development. <i>Blood</i> , 2021, 138, 1583-1589.	0.6	11
62	Inducing heat shock protein 70 expression provides a robust anti-thrombotic effect with minimal bleeding risk. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1722-1729.	1.8	10
63	Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis. <i>Leukemia</i> , 2021, 35, 245-249.	3.3	10
64	Factors influencing the use of thromboprophylaxis in cancer outpatients in clinical practice: A prospective study. <i>Thrombosis Research</i> , 2015, 136, 1145-1148.	0.8	9
65	Outcome of Patients with Venous Thromboembolism and Factor V Leiden or Prothrombin 20210 Carrier Mutations During the Course of Anticoagulation. <i>American Journal of Medicine</i> , 2017, 130, 482.e1-482.e9.	0.6	9
66	Causes of Death in Patients with Venous Thromboembolism Anticoagulated with Direct Oral Anticoagulants: A Systematic Review and Meta-Analysis. <i>Seminars in Thrombosis and Hemostasis</i> , 2018, 44, 377-387.	1.5	9
67	Fixed-dose low-molecular-weight heparin, bempiparin, in the long-term treatment of venous thromboembolism in patients with transient risk factors in standard clinical practice: the FLEBUS study. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 2504-2508.	1.9	8
68	Identification of 58 Mutations (26 Novel) in 94 of 109 Symptomatic Spanish Probands with Protein C Deficiency. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1409-1418.	1.8	8
69	Relationship between type of unprovoked venous thromboembolism and cancer location: An individual patient data meta-analysis. <i>Thrombosis Research</i> , 2019, 176, 79-84.	0.8	8
70	Inside the Thrombus: Association of Hemostatic Parameters With Outcomes in Large Vessel Stroke Patients. <i>Frontiers in Neurology</i> , 2021, 12, 599498.	1.1	8
71	Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients. <i>Leukemia and Lymphoma</i> , 2022, 63, 538-550.	0.6	8
72	Outcome of Cancer-Associated Venous Thromboembolism Is More Favorable among Patients with Hematologic Malignancies than in Those with Solid Tumors. <i>Thrombosis and Haemostasis</i> , 2022, 122, 1594-1602.	1.8	8

#	ARTICLE	IF	CITATIONS
73	Nuevos mecanismos en la trombosis venosa: inmunotrombosis. <i>Medicina Clínica</i> , 2019, 153, 78-81.	0.3	6
74	Evaluation of the factor V HR2 haplotype as a risk factor for ischemic cerebrovascular disease. <i>Haematologica</i> , 2003, 88, 236-7.	1.7	6
75	OC-08 Adjuvant bemiparin in small cell lung cancer: results from the ABEL study. <i>Thrombosis Research</i> , 2010, 125, S163.	0.8	5
76	Prediction of Major Bleeding in Anticoagulated Patients for Venous Thromboembolism: Comparison of the RIETE and the VTE-BLEED Scores. <i>TH Open</i> , 2021, 05, e319-e328.	0.7	5
77	Cancer screening after unprovoked venous thrombosis. <i>Lancet Oncology</i> , The, 2016, 17, 128-129.	5.1	4
78	PICO Questions and DELPHI Methodology for the Management of Venous Thromboembolism Associated with COVID-19. <i>Viruses</i> , 2021, 13, 2128.	1.5	4
79	[Translated article] Multidisciplinary consensus for the management of pulmonary thromboembolism. <i>Archivos De Bronconeumologia</i> , 2022, 58, T246-T254.	0.4	4
80	Acquired inhibitor of the intrinsic pathway in a non-haemophilic patient. control of bleeding by recombinant factor viia. <i>British Journal of Haematology</i> , 2002, 119, 284-285.	1.2	3
81	D-dimer level is not a prognostic biomarker specific of pulmonary embolism. <i>Critical Care Medicine</i> , 2008, 36, 653.	0.4	3
82	Reexposición temprana a heparina durante el trasplante cardiaco de pacientes con trombocitopenia inducida por heparina y asistencia ventricular. <i>Revista Espanola De Cardiologia</i> , 2015, 68, 638-640.	0.6	3
83	Outcomes beyond the Third Month of Anticoagulation in Patients Aged >75 Years with a First Episode of Unprovoked Venous Thromboembolism. <i>TH Open</i> , 2018, 02, e428-e436.	0.7	3
84	Improvement of appropriate pharmacological prophylaxis in hospitalised cancer patients with a multiscreen e-alert system: a single-centre experience. <i>Clinical and Translational Oncology</i> , 2019, 21, 805-809.	1.2	3
85	Performance of 18F-fluorodesoxyglucose positron-emission tomography/computed tomography for cancer screening in patients with unprovoked venous thromboembolism: Results from an individual patient data meta-analysis. <i>Thrombosis Research</i> , 2020, 194, 153-157.	0.8	3
86	Atypical bullous pemphigoid with extensive cutaneous and mucosal erosions associated with chronic lymphocytic leukemia. <i>Journal of Dermatology</i> , 2015, 42, 1128-1129.	0.6	2
87	Identification of new markers of recurrence in patients with unprovoked deep vein thrombosis by gene expression profiling: the retro study. <i>European Journal of Haematology</i> , 2016, 97, 128-136.	1.1	2
88	Prevention of venous thromboembolism in hematologic neoplasms: an expert consensus from SEHH "SETH". <i>Clinical and Translational Oncology</i> , 2022, 24, 770-783.	1.2	1
89	Long-Term Outcome of Critically Ill Advanced Cancer Patients Managed in an Intermediate Care Unit. <i>Journal of Clinical Medicine</i> , 2022, 11, 3472.	1.0	1
90	3B.1 Epidemiology of cancer and thrombosis in women " findings from the RIETE Registry. <i>Thrombosis Research</i> , 2007, 119, S30-S32.	0.8	0

#	ARTICLE	IF	CITATIONS
91	PO-02 Incidence of venous thromboembolism and prophylaxis use in ambulatory cancer patients receiving chemotherapy. <i>Thrombosis Research</i> , 2010, 125, S166.	0.8	0
92	P.32 The TEAM project: Spanish Registry of Thromboembolic Disease (TD) related with hormonal treatments, pregnancy, obstetrics complications or assisted reproductive procedures in women (ARP). <i>Thrombosis Research</i> , 2011, 127, S136-S137.	0.8	0
93	P.33 Study of variability in the management of thromboembolic disease (TD) in women in Spain: national multicenter study. <i>Thrombosis Research</i> , 2011, 127, S137.	0.8	0
94	Screening for occult malignancy with 18-F-FDG-PET/CT in patients with unprovoked venous thromboembolism. <i>Thrombosis Research</i> , 2012, 129, S176.	0.8	0
95	E-alerts for the prevention of venous thromboembolism in onco-hematological inpatients: pilot evaluation of reasons for physicians' refusal of pharmacological thromboprophylaxis. <i>Thrombosis Research</i> , 2012, 129, S181.	0.8	0
96	Abstract related to PL-22 Guidelines for antithrombotics in cancer patients. <i>Thrombosis Research</i> , 2012, 129, S194.	0.8	0
97	C0235 Identification of mutations in the protein C gene in a panel of 65 Spanish families with protein C deficiency. <i>Thrombosis Research</i> , 2012, 130, S110-S111.	0.8	0
98	C0374: Venous Thromboembolism in Hospitalised Cancer Patients Despite Electronic Alerts and Appropriate Prophylaxis with LMWH. Should We Consider Higher Doses in Some Patients?. <i>Thrombosis Research</i> , 2014, 133, S4-S5.	0.8	0
99	C0122: Identification of 6 Mutations in the Protein C Gene (PROC) in a Panel of 83 Spanish Families with Protein C Deficiency. <i>Thrombosis Research</i> , 2014, 133, S78.	0.8	0
100	Short-term Heparin Re-exposure During Heart Transplantation in Patients With Ventricular Assist Devices and Acute Heparin-induced Thrombocytopenia. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015, 68, 638-640.	0.4	0
101	Antidotes for the new oral anticoagulants: Reality and expectations. <i>Medicina Clínica (English)</i> Tj ETQq1 1 0.784314,rgBT /Oylock 10 0.1	0.1	0
102	BÃsqueda de cÃncer oculto en pacientes con tromboembolismo venoso: un dilema por resolver. <i>Angiologia</i> , 2016, 68, 456-458.	0.0	0
103	New mechanisms in venous thrombosis: Immunothrombosis. <i>Medicina ClÃnica (English Edition)</i> , 2019, 153, 78-81.	0.1	0
104	Differences in Venous Thromboembolism Prevention and Outcome between Hospitalized Patients with Solid and Hematologic Malignancies. <i>TH Open</i> , 2019, 03, e153-e156.	0.7	0
105	Multidisciplinary consensus for the management of pulmonary thromboembolism. <i>Archivos De Bronconeumologia</i> , 2021, , .	0.4	0
106	Impact of the mutation profile on thrombotic risk in cancer patients. <i>Revista Cl&#x00ed;nica Espan&#x00f5;la</i> , 2021, 222, 93-93.	0.3	0
107	Reply. <i>Journal of the American College of Cardiology</i> , 2021, 78, e129.	1.2	0
108	International Clinical Practice Guidelines for the Treatment and Prophylaxis of Thrombosis Associated with Central Venous Catheters in Patients with Cancer. <i>Blood</i> , 2012, 120, 4357-4357.	0.6	0

#	ARTICLE	IF	CITATIONS
109	Understanding the Cellular Origin and Pathogenic Transcriptional Programs in Multiple Myeloma (MM) and Light-Chain Amyloidosis (AL) through the Dissection of the Normal Plasma Cell (PC) Development. Blood, 2018, 132, 188-188.	0.6	0
110	Multidimensional Immunophenotyping Identifies Hallmarks of Systemic Light-Chain Amyloidosis (AL) and Maps the Disease in the Crossroad between MGUS and Multiple Myeloma (MM). Blood, 2018, 132, 3170-3170.	0.6	0
111	Sars-Cov-2 Infection and Systemic Light Chain Amyloidosis: The International Society of Amyloidosis' Survey. Blood, 2020, 136, 11-11.	0.6	0
112	CM-352 EFFICACY IN A MOUSE MODEL OF ANTICOAGULANT-ASSOCIATED INTRACRANIAL HAEMORRHAGE. Thrombosis and Haemostasis, 2022, 0, .	1.8	0